Wells Fargo analyst Mohit Bansal has maintained their neutral stance on BMY stock, giving a Hold rating today.
Mohit Bansal’s rating is based on several factors impacting Bristol-Myers Squibb’s financial outlook. The company’s revenue for the first quarter is expected to align with consensus estimates, approximately $10.7 billion, despite challenges from fourth-quarter stocking adjustments and headwinds from the redesign of Part D. However, these factors may lead to a slight earnings per share miss, estimated at around $0.04.
Additionally, while the launch of Cobenfy is showing positive early feedback and strong commercial access, the real impact on revenue is anticipated to occur in the second half of 2025 as prescriber traction increases. These mixed signals, with some positive developments and ongoing challenges, contribute to the Hold rating, suggesting that investors may want to maintain their current positions without making significant changes until more clarity emerges in the company’s financial performance.
Bansal covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Amgen. According to TipRanks, Bansal has an average return of 1.9% and a 48.64% success rate on recommended stocks.